Though AD pathology is nothing to sniff at, some features, notably neurodegeneration, have been vexingly hard to reproduce in animal models. Researchers at the National Institutes of Health, Bethesda, Maryland, have created a mouse model that selectively and reversibly overexpresses a mutant form of human amyloid precursor protein (APP) in the olfactory epithelium. It's among the first APP transgenic mice to show substantial neuron loss, which appears to occur in the absence of Aβ plaques. The findings, published in the September 28 issue of the Journal of Neuroscience, challenge the hypothesis that Aβ plaques are necessary for neurodegeneration, while the model provides new avenues to explore the mechanisms of APP toxicity.

"Up to now, none of the APP transgenic mice we have has consistently shown significant neurodegeneration," said Donna Wilcock of the University of Kentucky, who was not involved in the research. She added that neurodegeneration is a critical component of the Alzheimer's process. Scientists, including senior investigator Leonardo Belluscio of the National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, know that the olfactory system is among the first to succumb to the ill effects of Alzheimer's disease (AD) (see Bacon et al., 1998), and that amyloid pathology in the olfactory epithelium (OE) parallels brain pathology (see ARF related news story on Wesson et al., 2010; Arnold et al., 2010). They hypothesized that olfactory sensory neurons (OSNs), which detect scent information in the nasal cavity and send it to the brain's olfactory bulb, were more vulnerable to AD pathology than cortical cells, and might make a good model to study APP-induced neurodegeneration. Belluscio and colleagues generated two mouse lines: one that expressed human APP (hAPP) in mature OSNs; and one that expressed the protein in immature OSNs, each driven by promoters specific to those cell types.

When the mice were just three weeks old, the team saw four times as much apoptosis in hAPP-expressing cells as in controls, as evidenced by the presence of cleaved caspase-3 and TUNEL staining. Cell death occurred only in those subsets of cells that produced hAPP, leaving healthy neighboring cells unaffected. Immunoelectron microscopy turned up no evidence of Aβ plaques. In addition, hAPP-producing mature cells were more likely to be apoptotic than hAPP-positive immature neurons. This could mean mature cells may be more susceptible to hAPP's effects, the authors wrote.

"Trying to determine the basis of vulnerability [in the olfactory sensory neurons] may also give us insight as to why certain other brain regions are susceptible," Belluscio said.

The team, which included first author Ning Cheng of NINDS and Huaibin Cai of the National Institute on Aging, was able to control the expression of hAPP via the tetracycline-(tet-off)-transactivation system. Feeding the mice doxycycline halted hAPP expression within a week. The measure rescued hAPP-positive immature neurons, leaving significantly more proliferating cells and fewer apoptotic cells in the olfactory epithelium. But hAPP-producing mature cells weren't so lucky; the rescue only modestly improved cell survival. "We're quite interested in trying to understand what might be the basis for that difference," said Belluscio.

Along with hippocampal cells, neurons in the olfactory epithelium are among the first to suffer in the early stages of AD and other neurological disorders. Both regions are characterized by a relatively high cell turnover, which the authors suggest could be a contributing factor to their APP susceptibility.

"We really don't have a clue for why the olfactory system is so sensitive to many different disorders," said Donald Wilson of the New York University School of Medicine and the Nathan Kline Institute for Psychiatric Research, who added that much of the research has focused on more central structures. "It's nice that this paper emphasizes that these cells, at least in this model system, are very sensitive to APP."

The study does not resolve the controversy about whether Aβ plaques are a cause or effect in AD, or both. It suggests Aβ plaques are not necessary for neurodegeneration, but it falls short of pinpointing an exact mechanism for cell death. Soluble forms of Aβ, which many researchers believe are the most toxic, could be to blame (see ARF related news story on McDonald et al., 2010). The researchers note that in the olfactory epithelium of both mouse lines, levels of Aβ40 and Aβ42 were dramatically higher than in wild-type mice. Other research suggests, for example, that an extracellular domain of APP causes neuron loss via a "death receptor," which sets off an apoptotic cascade (see ARF related news story on Nikolaev et al., 2009). This new mouse model, which exhibits neurodegeneration relatively early in a specific set of cells that are readily accessible through the nose, may allow researchers to answer questions that might be harder to address by studying deeper brain regions, said Belluscio. Because the gene expression can be turned on and off, researchers can explore, for instance, whether APP causes lasting damage. In addition, he said, the model will shed light on this oft-overlooked brain region in AD.

"Because there's been so much focus on the cognitive dysfunctions that go along with these disorders, many other areas may actually have been neglected that could give important insight," Belluscio said.—Gwyneth Dickey Zakaib

Comments

Make a Comment

To make a comment you must login or register.

Comments on News and Primary Papers

  1. In my view, the importance of this study lies in the finding that APP-induced neurodegeneration is cell autonomous. This study makes clever use of cell-specific promoters to show that only the APP-overexpressing cells undergo apoptosis while the neighboring, non-expressing cells remain unharmed. The authors do not speculate on the mechanism of APP-induced neurodegeneration, but the most conservative interpretation of their data would suggest that the intracellular domain of APP is required for the observed lethal effect.

    Indeed, overexpression of APP intracellular domain (AICD) in vivo results in hippocampal neurodegeneration (1) and reduced neurogenesis (2) in transgenic mice. Also, overexpression of AICD has been shown to induce apoptosis in vitro in neuronal cells (3). Germane to the present observations, multiple lines of investigation (4-6) show that AICD is predominantly generated by β-secretase processing of APP.

    Since the transgenic mice used in the study by Cheng et al. expressed Swedish mutant APP (which preferentially undergoes β-processing), it is likely that the APP-overexpressing cells that underwent apoptosis/neurodegeneration had higher levels of AICD. Thus, there is no need to invoke a soluble factor, Aβ or otherwise (7), in the cell-autologous mechanism of APP-induced neurodegeneration reported here.

    References:

    . Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18367-72. PubMed.

    . APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One. 2010;5(7):e11866. PubMed.

    . Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. J Alzheimers Dis. 2000 Nov;2(3-4):289-301. PubMed.

    . Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci. 2009 Oct 15;122(Pt 20):3703-14. PubMed.

    . The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem. 2010 Dec 31;285(53):41443-54. PubMed.

    . Dual role of alpha-secretase cleavage in the regulation of gamma-secretase activity for amyloid production. J Biol Chem. 2010 Oct 15;285(42):32549-56. PubMed.

    . APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009 Feb 19;457(7232):981-9. PubMed.

    View all comments by Sanjay Pimplikar

References

News Citations

  1. Blunted Sense of Smell Parallels Pathology in AD, PD
  2. Bad Guys—Aβ Oligomers Live Up to Reputation in Human Studies
  3. Keystone: Death Receptor Ligand—New Role for APP, New Model for AD?

Paper Citations

  1. . Very early changes in olfactory functioning due to Alzheimer's disease and the role of apolipoprotein E in olfaction. Ann N Y Acad Sci. 1998 Nov 30;855:723-31. PubMed.
  2. . Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci. 2010 Jan 13;30(2):505-14. PubMed.
  3. . Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol. 2010 Apr;67(4):462-9. PubMed.
  4. . The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010 May;133(Pt 5):1328-41. PubMed.
  5. . APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009 Feb 19;457(7232):981-9. PubMed.

Further Reading

Primary Papers

  1. . In vivo olfactory model of APP-induced neurodegeneration reveals a reversible cell-autonomous function. J Neurosci. 2011 Sep 28;31(39):13699-704. PubMed.